ERBB2 and breast cancer: Compared with IDC-B, IMPC-B patients have a younger age of onset, higher proportion of central and upper-inner quadrant tumors, higher histological grade, higher lymph node metastasis rate, and a higher proportion of HER2-positive breast cancer and require postoperative adjuvant chemotherapy.